AIM: To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis. METHODS: A prospective and consecutive open trial was carried out. The study included 38 patients with upper digestive symptoms sufficiently severe to warrant endoscopic investigation. H pylori status was defined based both on histology and on positive (13)C-urea breath test. Drug regimen was a seven-day course of omeprazole, clarithromycin and furazolidone (100 mg, 200 mg if over 30 kg) twice daily. Eradication of H pylori was assessed two months after treatment by histology and (13)C -urea breath test. Further clinical evaluation was performed 7 d, 2 and 6 mo after the treatment. RESULTS: Thirty-eight patients (24 females, 14 males) were included. Their age ranged from 4 to 17.8 (mean 10.9 +/- 3.7) years. On intent-to-treat analysis (n = 38), the eradication rate of H pylori was 73.7% (95% CI, 65.2%-82%) whereas in per-protocol analysis (n = 33) it was 84.8% (95% CI, 78.5%-91%). All the patients with duodenal ulcer (n = 7) were successfully treated (100% vs 56.2% with antral nodularity). Side effects were reported in 26 patients (68.4%), mainly vomiting (14/26) and abdominal pain (n = 13). Successfully treated dyspeptic patients showed improvement in 78.9% of H pylori-negative patients after six months and in 50% of H pylori-positive patients after six months of treatment. CONCLUSION: Triple therapy with furazolidone achieves moderate efficacy in H pylori treatment. The eradication rate seems to be higher in patients with duodenal ulcer.
AIM: To evaluate the furazolidone-based triple therapy in children with symptomatic H pylori gastritis. METHODS: A prospective and consecutive open trial was carried out. The study included 38 patients with upper digestive symptoms sufficiently severe to warrant endoscopic investigation. H pylori status was defined based both on histology and on positive (13)C-urea breath test. Drug regimen was a seven-day course of omeprazole, clarithromycin and furazolidone (100 mg, 200 mg if over 30 kg) twice daily. Eradication of H pylori was assessed two months after treatment by histology and (13)C -urea breath test. Further clinical evaluation was performed 7 d, 2 and 6 mo after the treatment. RESULTS: Thirty-eight patients (24 females, 14 males) were included. Their age ranged from 4 to 17.8 (mean 10.9 +/- 3.7) years. On intent-to-treat analysis (n = 38), the eradication rate of H pylori was 73.7% (95% CI, 65.2%-82%) whereas in per-protocol analysis (n = 33) it was 84.8% (95% CI, 78.5%-91%). All the patients with duodenal ulcer (n = 7) were successfully treated (100% vs 56.2% with antral nodularity). Side effects were reported in 26 patients (68.4%), mainly vomiting (14/26) and abdominal pain (n = 13). Successfully treated dyspeptic patients showed improvement in 78.9% of H pylori-negative patients after six months and in 50% of H pylori-positive patients after six months of treatment. CONCLUSION: Triple therapy with furazolidone achieves moderate efficacy in H pylori treatment. The eradication rate seems to be higher in patients with duodenal ulcer.
Authors: R Dani; D M Queiroz; M G Dias; J M Franco; L C Magalhães; G S Mendes; L S Moreira; L P De Castro; N H Toppa; G A Rocha; M M Cabral; P G Salles Journal: Aliment Pharmacol Ther Date: 1999-12 Impact factor: 8.171
Authors: Roger Araujo Castillo; José Luis Pinto Valdivia; Dhanny Ramírez; Jaime Cok García; Alejandro Bussalleu Rivera Journal: Rev Gastroenterol Peru Date: 2005 Jan-Mar
Authors: L G V Coelho; L D Moretzsohn; W L S Vieira; M A Gallo; M C F Passos; J M Cindr; M C Cerqueira; L Vitiello; M L Ribeiro; S Mendonça; J Pedrazzoli-Júnior; L P Castro Journal: Aliment Pharmacol Ther Date: 2005-03-15 Impact factor: 8.171
Authors: P Moayyedi; S Soo; J Deeks; B Delaney; A Harris; M Innes; R Oakes; S Wilson; A Roalfe; C Bennett; D Forman Journal: Cochrane Database Syst Rev Date: 2005-01-25
Authors: S D Georgopoulos; S D Ladas; S Karatapanis; A Mentis; C Spiliadi; V Artikis; S A Raptis Journal: Dig Dis Sci Date: 2000-01 Impact factor: 3.199
Authors: W M Wong; S D Xiao; P J Hu; W H Wang; Q Gu; J Q Huang; H H-X Xia; S M Wu; C J Li; M H Chen; Y Cui; K C Lai; W H C Hu; C K Chan; S K Lam; B C-Y Wong Journal: Aliment Pharmacol Ther Date: 2005-01-01 Impact factor: 8.171
Authors: Alfredo Larrosa-Haro; Elsa Ofelia Martínez-Puente; Pedro Coello-Ramírez; Yolanda Alicia Castillo de León; María del Carmen Bojórquez-Ramos; Rocío Macías-Rosales; Osvaldo García-Salazar; Gonzalo Vázquez-Camacho; María Rosa Flores Márquez Journal: Rev Gastroenterol Mex Date: 2004 Apr-Jun